Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.

BACKGROUND: Development of countermeasures to bioterrorist threats such as those posed by the smallpox virus (variola), include vaccination and drug development. Selective activation of nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most successful strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: El Omari, K, Solaroli, N, Karlsson, A, Balzarini, J, Stammers, D
Formato: Journal article
Lenguaje:English
Publicado: 2006
_version_ 1826260839115522048
author El Omari, K
Solaroli, N
Karlsson, A
Balzarini, J
Stammers, D
author_facet El Omari, K
Solaroli, N
Karlsson, A
Balzarini, J
Stammers, D
author_sort El Omari, K
collection OXFORD
description BACKGROUND: Development of countermeasures to bioterrorist threats such as those posed by the smallpox virus (variola), include vaccination and drug development. Selective activation of nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most successful strategies for antiviral chemotherapy as demonstrated for anti-herpes drugs. Vaccinia virus TK is a close orthologue of variola TK but also shares a relatively high sequence identity to human type 2 TK (hTK), thus achieving drug selectivity relative to the host enzyme is challenging. RESULTS: In order to identify any differences compared to hTK that may be exploitable in drug design, we have determined the crystal structure of VVTK, in complex with thymidine 5'-triphosphate (dTTP). Although most of the active site residues are conserved between hTK and VVTK, we observe a difference in conformation of residues Asp-43 and Arg-45. The equivalent residues in hTK hydrogen bond to dTTP, whereas in subunit D of VVTK, Asp-43 and Arg-45 adopt a different conformation preventing interaction with this nucleotide. Asp-43 and Arg-45 are present in a flexible loop, which is disordered in subunits A, B and C. The observed difference in conformation and flexibility may also explain the ability of VVTK to phosphorylate (South)-methanocarbathymine whereas, in contrast, no substrate activity with hTK is reported for this compound. CONCLUSION: The difference in conformation for Asp-43 and Arg-45 could thus be used in drug design to generate VVTK/Variola TK-selective nucleoside analogue substrates and/or inhibitors that have lower affinity for hTK.
first_indexed 2024-03-06T19:12:05Z
format Journal article
id oxford-uuid:171d686c-8db7-4815-ba96-6a2c56ae986b
institution University of Oxford
language English
last_indexed 2024-03-06T19:12:05Z
publishDate 2006
record_format dspace
spelling oxford-uuid:171d686c-8db7-4815-ba96-6a2c56ae986b2022-03-26T10:35:15ZStructure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:171d686c-8db7-4815-ba96-6a2c56ae986bEnglishSymplectic Elements at Oxford2006El Omari, KSolaroli, NKarlsson, ABalzarini, JStammers, D BACKGROUND: Development of countermeasures to bioterrorist threats such as those posed by the smallpox virus (variola), include vaccination and drug development. Selective activation of nucleoside analogues by virus-encoded thymidine (dThd) kinases (TK) represents one of the most successful strategies for antiviral chemotherapy as demonstrated for anti-herpes drugs. Vaccinia virus TK is a close orthologue of variola TK but also shares a relatively high sequence identity to human type 2 TK (hTK), thus achieving drug selectivity relative to the host enzyme is challenging. RESULTS: In order to identify any differences compared to hTK that may be exploitable in drug design, we have determined the crystal structure of VVTK, in complex with thymidine 5'-triphosphate (dTTP). Although most of the active site residues are conserved between hTK and VVTK, we observe a difference in conformation of residues Asp-43 and Arg-45. The equivalent residues in hTK hydrogen bond to dTTP, whereas in subunit D of VVTK, Asp-43 and Arg-45 adopt a different conformation preventing interaction with this nucleotide. Asp-43 and Arg-45 are present in a flexible loop, which is disordered in subunits A, B and C. The observed difference in conformation and flexibility may also explain the ability of VVTK to phosphorylate (South)-methanocarbathymine whereas, in contrast, no substrate activity with hTK is reported for this compound. CONCLUSION: The difference in conformation for Asp-43 and Arg-45 could thus be used in drug design to generate VVTK/Variola TK-selective nucleoside analogue substrates and/or inhibitors that have lower affinity for hTK.
spellingShingle El Omari, K
Solaroli, N
Karlsson, A
Balzarini, J
Stammers, D
Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
title Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
title_full Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
title_fullStr Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
title_full_unstemmed Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
title_short Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
title_sort structure of vaccinia virus thymidine kinase in complex with dttp insights for drug design
work_keys_str_mv AT elomarik structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT solarolin structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT karlssona structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT balzarinij structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign
AT stammersd structureofvacciniavirusthymidinekinaseincomplexwithdttpinsightsfordrugdesign